Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

被引：0
作者：
Michael Guger
Christian Enzinger
Fritz Leutmezer
Franziska Di Pauli
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
机构：
[1] Kepler University Hospital GmbH,Clinic for Neurology 2, Med Campus III
[2] Johannes Kepler University Linz,Medical Faculty
[3] Medical University of Graz,Department of Neurology
[4] Medical University of Vienna,Department of Neurology
[5] Medical University of Innsbruck,Clinical Department of Neurology
[6] Paracelsus Medical University and Salzburger Landeskliniken,Department of Laboratory Medicine
[7] Heinrich-Heine-University,Department of Neurology, Medical Faculty
[8] Hermesoft,undefined
[9] Data management,undefined
[10] Hermesoft,undefined
[11] Statistics,undefined
来源：
Journal of Neurology | 2021年 / 268卷
关键词：
Disability progression; Long-term; Multiple sclerosis; Natalizumab; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4303 / 4310
页数：7
相关论文
共 50 条
  • [31] Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
    Planas, Raquel
    Martin, Roland
    Sospedra, Mireia
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 25 - 33
  • [32] Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
    Iaffaldano, Pietro
    Lucisano, Giuseppe
    Caputo, Francesca
    Paolicelli, Damiano
    Patti, Francesco
    Zaffaroni, Mauro
    Brescia Morra, Vincenzo
    Pozzilli, Carlo
    De Luca, Giovanna
    Inglese, Matilde
    Salemi, Giuseppe
    Maniscalco, Giorgia Teresa
    Cocco, Eleonora
    Sola, Patrizia
    Lus, Giacomo
    Conte, Antonella
    Amato, Maria Pia
    Granella, Franco
    Gasperini, Claudio
    Bellantonio, Paolo
    Totaro, Rocco
    Rovaris, Marco
    Salvetti, Marco
    Torri Clerici, Valentina Liliana Adriana
    Bergamaschi, Roberto
    Maimone, Davide
    Scarpini, Elio
    Capobianco, Marco
    Comi, Giancarlo
    Filippi, Massimo
    Trojano, Maria
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [33] Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study
    Horakova, Dana
    Uher, Tomas
    Krasensky, Jan
    Seidl, Zdenek
    Ribbens, Annemie
    Van Hecke, Wim
    Billiet, Thibo
    Koendgen, Harold
    Freudensprung, Ulrich
    Hyde, Robert
    Vaneckova, Manuela
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [34] Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
    Tobias Monschein
    Sarinah Dekany
    Tobias Zrzavy
    Markus Ponleitner
    Patrick Altmann
    Gabriel Bsteh
    Barbara Kornek
    Paulus Rommer
    Christian Enzinger
    Franziska Di Pauli
    Jörg Kraus
    Thomas Berger
    Fritz Leutmezer
    Michael Guger
    Journal of Neurology, 2023, 270 : 3779 - 3786
  • [35] Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
    Monschein, Tobias
    Dekany, Sarinah
    Zrzavy, Tobias
    Ponleitner, Markus
    Altmann, Patrick
    Bsteh, Gabriel
    Kornek, Barbara
    Rommer, Paulus
    Enzinger, Christian
    Di Pauli, Franziska
    Kraus, Jorg
    Berger, Thomas
    Leutmezer, Fritz
    Guger, Michael
    JOURNAL OF NEUROLOGY, 2023, 270 (08) : 3779 - 3786
  • [36] Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study
    O'Connor, Paul
    Goodman, Andrew
    Kappos, Ludwig
    Lublin, Fred
    Polman, Chris
    Rudick, Richard A.
    Hauswirth, Kathy
    Cristiano, Lynda M.
    Forrestal, Fiona
    Duda, Petra
    NEUROLOGY, 2014, 83 (01) : 78 - 86
  • [37] Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
    Chisari, Clara G.
    Aguglia, Umberto
    Amato, Maria Pia
    Bergamaschi, Roberto
    Bertolotto, Antonio
    Bonavita, Simona
    Morra, Vincenzo Brescia
    Cavalla, Paola
    Cocco, Eleonora
    Conte, Antonella
    Cottone, Salvatore
    De Luca, Giovanna
    Di Sapio, Alessia
    Filippi, Massimo
    Gallo, Antonio
    Gasperini, Claudio
    Granella, Franco
    Lus, Giacomo
    Maimone, Davide
    Maniscalco, Giorgia Teresa
    Marfia, Girolama
    Moiola, Lucia
    Paolicelli, Damiano
    Pesci, Ilaria
    Ragonese, Paolo
    Rovaris, Marco
    Salemi, Giuseppe
    Solaro, Claudio
    Totaro, Rocco
    Trojano, Maria
    Vianello, Marika
    Zaffaroni, Mauro
    Lepore, Vito
    Patti, Francesco
    NEUROTHERAPEUTICS, 2024, 21 (04)
  • [38] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Takahiko Saida
    Qi Hao
    Michihiro Kanda
    Yumiko Tani
    BMC Neurology, 23
  • [39] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Saida, Takahiko
    Hao, Qi
    Kanda, Michihiro
    Tani, Yumiko
    BMC NEUROLOGY, 2023, 23 (01)
  • [40] Early Predictors of Disability and Cognition in Multiple Sclerosis Patients: A Long-Term Retrospective Analysis
    Virgilio, Eleonora
    Vecchio, Domizia
    Sarnelli, Maria Francesca
    Solara, Valentina
    Cantello, Roberto
    Comi, Cristoforo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
12345